[IC‐P‐039]: VALIDATION OF A SIMPLE SEVERITY SCALE FOR ASSESSING ARIA‐E
Luc Bracoud(BioClinica (United States)), Joyce Suhy(BioClinica (United States)), Achim Gass(Heidelberg University), Derk D. Purcell(BioClinica (United States)), Camilla Lindan(Kaiser Permanente San Francisco Medical Center), Jerome Barakos(Sutter Health), Jochen B. Fiebach(Pathodiagnostik Berlin), Erik Gaensler(Alta Bates Summit Medical Center)
Cited by 1
Related Papers
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696